Franklin Templeton Insights: UK Equities: Where Next?

Any discussion on the macro outlook for the UK economy and the equity market needs to start with the topic of inflation. Early last year, the market was panicking about the prospect of inflation—but largely thinking it would likely be “transitory”. Those fears materialised with some stronger-than-expected inflation figures throughout 2021. The Consumer Price Index rose to a 30-year high in December of 2021 of 5.4%, year-on-year, so we are really stretching the definition of transitory to its limit now. Rising inflation continues to affect us all, and how policymakers will respond is top of mind today. But it is important to remember that in order to generate a sustained inflationary spiral akin to the 1970s, we would need to see further, ever-higher price increases as compared against the prior year’s numbers. As the mathematics gets a little bit tougher, we think the inflation numbers should moderate over the course of the year and beyond.

UK Equities Where Next Article Image 1

…and Interest Rates

Tackling Inflation is certainly on the minds of central bankers across the globe. Before COVID-19, market expectations were for UK interest rates to take several years to reach 1%. In the depths of the pandemic, this expectation collapsed to price in rates barely budging above the zero bound. But those expectations have markedly changed. On 3 February 2022, the Bank of England increased its base rate from 0.25% to 0.50%, and the market expects three further rate hikes this year, moving the rate up to the 1% level and beyond. Whilst these forecasts seem aggressive relative to the recent rate environment, we mustn’t forget that base rates of 5% and above were commonplace before the 2008 global financial crisis.

UK Equities Where Next Article Image 2

But What Impact Does This Have on the UK Market?

It is important to understand the composition of equity indices before assessing the relative impact of inflation and rising interest rates. Drilling down into the UK equity market, we encounter dominant sectors such as banks, life assurance, specialist financials and resources, all of which are beneficiaries of inflation and rising interest rates. Regulatory price rises and the ability to pass through increasing input costs to the end consumer are key to inflation protection, and considering the UK economy also has significant exposure to utilities, tobacco, pharmaceuticals and food retail, we believe the UK market has a strong foundation from which to “weather the storm”.

The UK equity market has lagged the United States for some time, most recently due to the paucity of high-growth (often zero-profit) stocks where the terminal value is discounted from earnings projected many years into the future. With rising interest rates also increasing the discount rate for equity valuations, these high-growth stocks are disproportionately sensitive to inflation and the consequent central bank response. It is such considerations that suggest to us that market conditions are becoming more favourable for the UK market on both an absolute and relative basis, as intimated by the strong relative performance of the United Kingdom market thus far in 2022.

…And the UK Consumer?

There are undoubted pressures on the UK consumer in 2022 as rising National Insurance, energy bills and general inflation eat into discretionary spending. Despite the shift in interest rate expectations, it is important to consider the mechanisms through which that feeds onto the economy. We are starting from a position where mortgage payments are at historically low proportion percentage of post-tax earnings, providing a cushion against rising rates. What is more, with 80% of mortgages currently on fixed-rate deals (indeed the majority on five-year deals),1 any direct impact through this mechanism to consumer spending is likely to be lagged. The great imponderable through all this is the likely usage or otherwise of the excess saving that has compounded throughout the pandemic, some £200bn of additional firepower being reported.2 Moreover, when you consider strong employment data in the form of record job vacancies and business confidence to grow human capital, there are still plenty of signs of life in the UK economy.

UK Equities Where Next Article Image 3

Where Are UK Valuations?

Comparing the UK market to those overseas, relative valuations peaked in 2016 ahead of the Brexit referendum, and have been falling ever since. Looking at forward price/earnings (P/E) ratios, UK stocks look very inexpensive on a global basis, with a P/E of 12.5x versus around 20x for the MSCI World Index.3 Much of this is due to the under-exposure to expensive growth stocks that have performed so well in recent years. However, we remain confident that the United Kingdom offers reasonable growth at very reasonable prices—forecast gross domestic product remains at around 5% and on an upward trajectory to pre-pandemic levels.

Enhanced merger & acquisition activity remains supportive to UK valuations, and we are also noticing a reversal in a long-term decreasing trend of new initial public offering (IPO) listings, all indicative of attractively valued equity capital. We believe the UK market is adequately protected against further de-ratings and becomes increasingly attractive when considered alongside the prospect of a healthy 4% dividend yield.

UK Equities Where Next Article Image 4
UK Equities Where Next Article Image 5


 

Franklin Templeton Key risks & Disclaimers:

Important Legal Information

This material is intended to be of general interest only and should not be construed as individual investment advice or a recommendation or solicitation to buy, sell or hold any security or to adopt any investment strategy. It does not constitute legal or tax advice.

The views expressed are those of the investment manager and the comments, opinions and analyses are rendered as of publication date and may change without notice. The information provided in this material is not intended as a complete analysis of every material fact regarding any country, region or market.

Data from third party sources may have been used in the preparation of this material and Franklin Templeton (“FT”) has not independently verified, validated or audited such data. FT accepts no liability whatsoever for any loss arising from use of this information and reliance upon the comments, opinions and analyses in the material is at the sole discretion of the user.

Products, services and information may not be available in all jurisdictions and are offered outside the U.S. by other FT affiliates and/or their distributors as local laws and regulation permits. Please consult your own professional adviser or Franklin Templeton institutional contact for further information on availability of products and services in your jurisdiction.

Issued in the U.S. by Franklin Templeton Distributors, Inc., One Franklin Parkway, San Mateo, California 94403-1906, (800) DIAL BEN/342-5236, franklintempleton.com—Franklin Templeton Distributors, Inc. is the principal distributor of Franklin Templeton’s U.S. registered products, which are not FDIC insured; may lose value; and are not bank guaranteed and are available only in jurisdictions where an offer or solicitation of such products is permitted under applicable laws and regulation.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

What are the risks?

All investments involve risks, including possible loss of principal. The value of investments can go down as well as up, and investors may not get back the full amount invested. Brokerage commissions and ETF expenses will reduce returns. ETF shares may be bought or sold throughout the day at their market price on the exchange on which they are listed. ETFs trade like stocks, fluctuate in market value and may trade above or below the ETF’s net asset value. However, there can be no guarantee that an active trading market for ETF shares will be developed or maintained or that their listing will continue or remain unchanged. While the shares of ETFs are tradable on secondary markets, they may not readily trade in all market conditions and may trade at significant discounts in periods of market stress.



MeDirect Disclaimers:

This information has been accurately reproduced, as received from Franklin Templeton Investment Management Limited (FTIML). No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.

The financial instruments discussed in the document may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.

If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your investment return therefrom. The performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. Any decision to invest in a mutual fund should always be based upon the details contained in the Prospectus and Key Investor Information Document (KIID), which may be obtained from MeDirect Bank (Malta) plc.

You are leaving medirect.com.mt

Please be aware that the external site policies, or those of another MeDirect website, may differ from this website’s terms and conditions and privacy policy. The next website will open in a new browser window or tab.

 

Note: MeDirect is not responsible for any content on third party sites, nor does a link suggest endorsement of those sites and/or their content.

Login

We strive to ensure a streamlined account opening process, via a structured and clear set of requirements and personalised assistance during the initial communication stages. If you are interested in opening a corporate account with MeDirect, please complete an Account Opening Information Questionnaire and send it to corporate@medirect.com.mt.

For a comprehensive list of documentation required to open a corporate account please contact us by email at corporate@medirect.com.mt or by phone on (+356) 2557 4444.